Collectively, both the in vitro and in vivo results demonstrate that the immunogenic P1 peptide derived from CLDN18 (exon 5)-ARHGAP26 (exon 12) fusion can generate NRT cells with specific and promising cytotoxicity against target tumor cells. Here, CLDN18 is linked to neoplasm.